CA2303888A1 - Medical emulsion lubricant - Google Patents
Medical emulsion lubricant Download PDFInfo
- Publication number
- CA2303888A1 CA2303888A1 CA002303888A CA2303888A CA2303888A1 CA 2303888 A1 CA2303888 A1 CA 2303888A1 CA 002303888 A CA002303888 A CA 002303888A CA 2303888 A CA2303888 A CA 2303888A CA 2303888 A1 CA2303888 A1 CA 2303888A1
- Authority
- CA
- Canada
- Prior art keywords
- oil
- emulsion
- lubricant
- medical
- medical lubricant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/32—Surgical cutting instruments
- A61B17/3205—Excision instruments
- A61B17/3207—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions
- A61B17/320758—Atherectomy devices working by cutting or abrading; Similar devices specially adapted for non-vascular obstructions with a rotating cutting instrument, e.g. motor driven
Abstract
A medical lubricant suitable for injection into the blood stream of a patient.
The lubricant is suitable for use with rotating equipment such as atherectomy drive shafts moving within sheaths and over guide wires. The lubricant is an oil-in-water emulsion including a surfactant and a co-surfactant. The lubricant can include a cryogenic agent and a pH buffer and be pH adjusted.
One lubricant includes olive oil as an emulsified oil, egg yolk phospholipid as a surfactant, sodium deoxycholate as a co-surfactant, glycerin as a cryogenic agent, L-histidine as a pH buffer, and is pH adjusted using sodium hydroxide. The lubricant can withstand freeze/thaw cycles as well as saline dilution, heating, and shear stress without significant creaming, separation, or unacceptable 15 increases in oil droplet size. Compared to saline, the lubricant provides significantly increased lubrication efficiency for rapidly moving parts.
The lubricant is suitable for use with rotating equipment such as atherectomy drive shafts moving within sheaths and over guide wires. The lubricant is an oil-in-water emulsion including a surfactant and a co-surfactant. The lubricant can include a cryogenic agent and a pH buffer and be pH adjusted.
One lubricant includes olive oil as an emulsified oil, egg yolk phospholipid as a surfactant, sodium deoxycholate as a co-surfactant, glycerin as a cryogenic agent, L-histidine as a pH buffer, and is pH adjusted using sodium hydroxide. The lubricant can withstand freeze/thaw cycles as well as saline dilution, heating, and shear stress without significant creaming, separation, or unacceptable 15 increases in oil droplet size. Compared to saline, the lubricant provides significantly increased lubrication efficiency for rapidly moving parts.
Description
MEDICAL EMULSION LUBRICANT
Field of the Invention This invention relates to a lubricating composition for use with biomedical devices. More pa~~ticularly;, this invention relates to an injectable emulsion capable of being used within human arteries during a rotational atherectomy procedure.
Background of the Invention It is well known that, for various reasons, humans can develop a condition in which a type of pL~que or hard deposit builds up along the walls of the blood vessels, thereby partially blocking the blood flow and causing severe medical conditions.
Several different procedures have been developed for dealing with this situation. One such procedure i,s rotational atherectomy, in which a rotary mechanical system removes relatively hard intravascular deposits from the walls of human arteries by differentially cutting away the inelastic, hardened deposits while sparing the soft, elastic tissue of the inner lining of the human blood vessels. The seminal patent that discloses a device for performing this procedure is U.S. Patent No. 4,990,134 (Ruth) entitled "TRANS:LUMINAL MICRODISSECTION DEVICE", the disclosure of which is incorporated herein by reference.
In the corrunercially available device described in U.S. Patent No. 4,990,134, known as the Rotablator~, an ellipsoidal burr coated with tiny diamond chips is rotated at a speed of at least approximately 155,000 revolutions per minute.
The burr is connected to a drive motor capable of high speed rotation via a hollow, flexible, helically-wound drive shaft, and is routed through the blood vessel over a narrow guide wire; that extends through the central bore of the burr and its drive shaft.
When this device: is operated, the burr preferentially cuts hard, inelastic material (plaque) while sparing soft, elastic material (tissue) and generates microscopic debris fi-agments that are sufficiently small in size so as to pass through even the narrowest vascular channels (;capillary beds) without clogging them.
This Rotablator~ atherectomy device, as well as any other microdissection device that involves rotational ablation, necessarily generates thermal energy during its rotation. Fair this reason, as disclosed in U.S. Patent No.4,990,134, a biocompatible saline solution is infused through a plastic sheath within which the drive shaft rotates, to cool the sliding interface during operation.
In addition to performing a cooling function, some lubrication is needed to prevent wear caused by rotational friction between the guide wire and the drive shaft or between the driive shaft and the plastic sheath. The major factors that affect wear in this type of rotational contact are load, temperature, surface speed, surface finish, surface hardness, contact area, time, and the type, amount and viscosity of the lubricant.
During extended operation of the device, however, additional lubrication should be provided to sustain the performance of the guide wire, the drive shaft and the sheath. Such a lubricant, if infused through the device from outside the patients' body, must of course, be non-toxic and safe for arterial use. In addition, to be effective in use with the Rotablator advancer/guide wire system, the lubricant should be able to withstand shear stresses at 50° C and should not promote the agglomeration of :ablated plaque particles.
Injectable oil-in-water emulsions are currently being used for two clinical applications. The; first is for parenteral or intravenous nutrition, as a source of fat calories and essential fatty acids. Examples include Intralipid~, available from Pharmacia and Upjohn and Liposyn, available from Abbott Laboratories.
Emulsions are also being used as a vehicle for poorly water-soluble lipophilic drugs that cannot be injected directly. Examples include Diprivan, containing the anesthetic drug proposal, and Diazemuls, containing the drug diazepam.
Lipid emulsions are inherently unstable. No commercially available lipid emulsion is stable; following dilution in physiological (0.9% w/v) salt solution. This instability is manifested by formation of large droplets of non-emulsified oil on the surface as well as by a shift in droplet size distribution towards much larger diameters.
Such changes ofl:en occur within the first hour following dilution in saline and are accelerated by heating or by applying any shear force. The relatively low pH
and high ionic strength of saline contributes to this effect.
Field of the Invention This invention relates to a lubricating composition for use with biomedical devices. More pa~~ticularly;, this invention relates to an injectable emulsion capable of being used within human arteries during a rotational atherectomy procedure.
Background of the Invention It is well known that, for various reasons, humans can develop a condition in which a type of pL~que or hard deposit builds up along the walls of the blood vessels, thereby partially blocking the blood flow and causing severe medical conditions.
Several different procedures have been developed for dealing with this situation. One such procedure i,s rotational atherectomy, in which a rotary mechanical system removes relatively hard intravascular deposits from the walls of human arteries by differentially cutting away the inelastic, hardened deposits while sparing the soft, elastic tissue of the inner lining of the human blood vessels. The seminal patent that discloses a device for performing this procedure is U.S. Patent No. 4,990,134 (Ruth) entitled "TRANS:LUMINAL MICRODISSECTION DEVICE", the disclosure of which is incorporated herein by reference.
In the corrunercially available device described in U.S. Patent No. 4,990,134, known as the Rotablator~, an ellipsoidal burr coated with tiny diamond chips is rotated at a speed of at least approximately 155,000 revolutions per minute.
The burr is connected to a drive motor capable of high speed rotation via a hollow, flexible, helically-wound drive shaft, and is routed through the blood vessel over a narrow guide wire; that extends through the central bore of the burr and its drive shaft.
When this device: is operated, the burr preferentially cuts hard, inelastic material (plaque) while sparing soft, elastic material (tissue) and generates microscopic debris fi-agments that are sufficiently small in size so as to pass through even the narrowest vascular channels (;capillary beds) without clogging them.
This Rotablator~ atherectomy device, as well as any other microdissection device that involves rotational ablation, necessarily generates thermal energy during its rotation. Fair this reason, as disclosed in U.S. Patent No.4,990,134, a biocompatible saline solution is infused through a plastic sheath within which the drive shaft rotates, to cool the sliding interface during operation.
In addition to performing a cooling function, some lubrication is needed to prevent wear caused by rotational friction between the guide wire and the drive shaft or between the driive shaft and the plastic sheath. The major factors that affect wear in this type of rotational contact are load, temperature, surface speed, surface finish, surface hardness, contact area, time, and the type, amount and viscosity of the lubricant.
During extended operation of the device, however, additional lubrication should be provided to sustain the performance of the guide wire, the drive shaft and the sheath. Such a lubricant, if infused through the device from outside the patients' body, must of course, be non-toxic and safe for arterial use. In addition, to be effective in use with the Rotablator advancer/guide wire system, the lubricant should be able to withstand shear stresses at 50° C and should not promote the agglomeration of :ablated plaque particles.
Injectable oil-in-water emulsions are currently being used for two clinical applications. The; first is for parenteral or intravenous nutrition, as a source of fat calories and essential fatty acids. Examples include Intralipid~, available from Pharmacia and Upjohn and Liposyn, available from Abbott Laboratories.
Emulsions are also being used as a vehicle for poorly water-soluble lipophilic drugs that cannot be injected directly. Examples include Diprivan, containing the anesthetic drug proposal, and Diazemuls, containing the drug diazepam.
Lipid emulsions are inherently unstable. No commercially available lipid emulsion is stable; following dilution in physiological (0.9% w/v) salt solution. This instability is manifested by formation of large droplets of non-emulsified oil on the surface as well as by a shift in droplet size distribution towards much larger diameters.
Such changes ofl:en occur within the first hour following dilution in saline and are accelerated by heating or by applying any shear force. The relatively low pH
and high ionic strength of saline contributes to this effect.
Commercial lipid emulsions separate into oil and water layers upon thawing after storage at frExzing temperatures. For this reason, special care must be taken when shipping in winter through geographic areas having below freezing temperatures. It is preferred that the lubricant be an emulsion which is stable in saline and stable upon freezing with subsequent thawing. The present invention meets these needs and overcomes other deficiencies in the prior art.
What would be desirable is an improved, pharmacologically compatible medical lubricant. What has not been provided is an injectable medical lubricant suitable for lubricating rotating and otherwise moving medical devices.
Summar~r of the Invention The present inventian includes a medical lubricant suitable for injection into a patient. The lubri<;ant is an oil-in-water emulsion including an oil, a surfactant, a co-surfactant and water. The lubricant preferably also includes a cryogenic agent, a pH
buffer, and a pre.~ervative. The lipid emulsion preferably has a mean particle or droplet diameter of less then 1 micrometer, most preferably less than about 0.5 micrometer. 'Che lubricant can be subjected to substantial shear by a rotating member, exhibits a commercially acceptable shelf life during storage under ambient temperatures, and is able to withstand freeze-thaw cycles without substantial degradation. The lubricant can be diluted in physiological saline for injection and maintains suitable emulsion droplet size after such dilution.
The oil can be a vegetable oil or a medium chain triglyceride. The preferred oil is refined olive oil, which preferably comprises mostly mono-unsaturated oleic acid. The oil can lubricate medical devices such as rotating drive shafts in atherectomy devices, thereby reducing wear on moving parts. A mean droplet size of less than about 1 micrometer allows injection into the bloodstream and subsequent absorption by the body without ill effect. The emulsion most preferably includes about 20 g refined olive oil per 100 mL emulsion.
The surfactant can be a phospholipid, preferably purified egg yolk phospholipids. The surfactant stabilizes the oil droplets dispersed in the continuous aqueous phase. The present invention preferably includes about 1.2 g egg yolk phospholipids per 100 mL emulsion.
The co-surfactant can he a salt of a bile acid, most preferably sodium deoxycholate. The co-surfactant significantly improves droplet stability after saline dilution, heating, and exposure to high shear forces. Droplet stability includes the resistance to forn.~ation of larger droplets, creaming, and formation of a separate oil layer. Bile salt, acting in conjunction with glycerin, provides improved freeze-thaw stability. Applicants believe the bile salt also improves lubricity by acting as a wetting agent, improving 'the coating of moving metal parts. The present invention most preferably includes, about 0.,4 g bile salt per 100 mL emulsion.
The . cryogenic agent can be refined propylene glycol or glycerin, preferably glycerin. glycerin also provides improved lubricity. The present invention preferably includes about 10 g glycerin per 100 mL emulsion.
The pH buffer is preferably an amino acid buffer. The pH buffer imparts improved droplet stability in a saline diluent. The amino acid buffer is most preferably L-histidine in a concentration of about 0.16 g per 100 mL emulsion.
The preservative is preferably a heavy metal chelator such as disodium EDTA
EDTA, and the histidine buffer, serve as antioxidants, protecting unsaturated fatty acids found in egg yolk phospholipids. The antioxidants provide an extended shelf life for the emulsion at room 'temperature and inhibit peroxide formation during clinical use. Disodium EL>TA is preferably present in about 0.014 g per 100 mL
emulsion.
The emulsion preferably has the pH adjusted to between about 8.3 and 8.8 with a base such as sodium. hydroxide. This pH range optimizes the emulsion stability in the presence of non-buffered saline, which is slightly acidic. Sodium hydroxide can be present in about 3.0 mEq per liter of emulsion.
An emulsion according to the present invention can be prepared by combining refined olive oil, 1.2% egg yolk phospholipid, 0.16% L-histidine (IOmIVn, 0.014%
disodium EDTA (~0.5 mlVn, and water, followed by ultrasonic processing for about 15 minutes. The emulsion can also be prepared using high pressure homogenization techniques well known to those skilled in the art.
In use, the: emulsion can be stored for at least 18 months, preferably twenty-four (24) months at room temperature. The emulsion can be stored frozen at minus 30 degrees C, and then thawed without causing significant changes in droplet size distribution. The emulsion can be added to normal, unbuffered 0.9% saline solution. One anticipated use is injection of the emulsion into an IV bag of saline, thereby diluting the emulsion. The diluted emulsion can be infused from the IV
bag through a catheter tube housing a rotating member such as an atherectomy drive shaft or an ultrasonic probe drive shaft. The emulsion serves to lubricate the moving parts and can thereafter enter the blood stream of a patient without ill effect.
WO 99/15152 PG'T/US98/19119 yetailed Description of the Preferred Embodiment In a prefewed embodiment of the invention, the oil-in-water emulsion lubricant comprises a mixture of water, oil, a surfactant, a co-surfactant, a phospholipid, a cryogenic agent, a pH buffer and a preservative.
' Preferably the oil used in the lipid emulsion lubricant is a liquid at room temperature, most preferably olive oil. Chemically, olive oil contains mostly mono-unsaturated oleic acid. Different oil bases, such as either soybean oil, which contains a mixture of polyunsaturated fatty acids, mainly Ci4, C16 and Cig, or medium chain triglycerides {MC'.C) may also be used, especially with varying concentrations of the other ingredients ;and with different surfactants. Almond oil, cocorntt oil, corn oil, cotton seed oil, marine oil, palm kernel oil, peanut oil, safflower oil, sesame oil, sunflower oil, and physical or interesterified mixtures thereof can also be used. These other oil bases, however, are not as effective as olive oil. Quite surprisingly, we found that olive oil emulsions lubricate better than soybean oil emulsions.
The 1 S lubricant reduces wear on moving components. In a preferred embodiment of the invention, the concentratian of olive oil in the lubricant is from about 5 to about 40 g/100 mL emulsion, more preferably about 15 to about 25 g/100 mL emulsion, and is most preferably about 2G g/100 mL emulsion.
An emulsion is a dispersion of one immiscible liquid within another, commonly oil-in-water. An emulsifier is a surface active agent designed to coat and stabilize the dispersed droplets against coalescence. However, in certain formulations, this dispersion is insufficiently stabilized by the primary emulsifier which is typically added at concentrations of about 1-5% w/v. In such cases, a second surface active agent, known as a co-surfactant, may be added. A co-surfactant is typically used at a fractional concenlxadon of the primary emulsifier, e.g., 0.1-1.0%. In principle, co surfactants are added to accomplish specific tasks such as enhancing electrostatic surface charge on the dispersed droplets or strengthening the interfacial film between oil and water. In reality, it is quite difficult to predict in advance which co-surfactant, if any, will stabilize a novel emulsion formulation under specific environmental conditions.
A primary emulsifier in the lipid emulsion lubricant could, for example, be selected from a group of phospholipids such as soy bean or egg yolk phospholipids.
A preferred phospholipid is egg yolk phospholipid, preferably present in a concentration of about 0.3 to about 3 g/100 mL emulsion, more preferably about 0.6 to about 1.8 g/10~D mL emulsion, most preferably about 1.2 g/100 mL emulsion.
The co-surfactant could be, for example, PEG-400 (polyethylene glycol), Pluronic F68 (a nonionic, polyoxethylene-polyoxypropylene block copolymer, BASF) dimyristyl phosphatidyl glycerin (DMPG) , or the salt of a bile acid. When PEG-is used, it can be present at about 5%, we:ight/volume. When Pluronic F68 is used, it can be present at about 1%, weight/volume. Preferably, the co-surfactant is the salt of a bile acid such as cholic acid, deoxycholic acid, taurocholic acid or nnixtures thereof. Most preferably, the co-surfactant is sodium de:oxycholate, as it is somewhat more effective in reducing wear than DMPG. in the present invention, the superiority of sodium deox,/cholate over other tested co-surfactants was unexpected and unpredicted. In a preferred embodiment, sodium deoxycholate is present at a concentration of about 0.04 to about 4 g/100 mL emulsion, more preferably about 0.2 to about 0.8 g/100 mL emulsion, most preferably about 0.4 g/100 mL emulsion.
A preferred cryogenic agent is refined propylene glycol or glycerin, most preferably glycervi. glycerin serves to provide freeze tolerance and improves the overall lubricating properties of the emulsion. glycerin is preferably present at a concentration of about 1 to about 30 g/100 mI, emulsion, more preferably about 2 to about 20 g/100 niL emulsion, most preferably about 10 g/100 mL emulsion.
A preferred pH buffer is an amino acid buffer, for example, alanine, aspartic acid, glycine, histiidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, valine or mixtures thereof. A preferred amino acid buffer is histidine.
I~stidine contributes significant pH buffering capacity in the critical pH 6 to 8 range, having a pKa, of about 6Ø This pH buffering contributes to emulsion stability after dilution in saline. In addition, histidine serves as an antioxidant, specifically a hydroxy radical scavenger. Histidine is preferably present at a concentration of about 0.01 to about 1 g/100 mL emulsion, mare preferably about 0.05 to about 0.3 g/100 mL
emulsion, most preferably about O.lti g/100 mL emulsion.
A preferred preservative is a heavy metal chelator such as disodium EDTA.
The combination of EDT'A and histidine serves as a potent antioxidant to protect unsaturated fatty acids found in egg yolk phospholipids. This antioxidant system serves both to protect the emulsion in the bottle during prolonged storage at room temperature as v~rell as to inhibit peroxide formation during clinical use.
Disodium EDTA is preferably present at a concentration of about 0.001 to about 0.1 g/100 mL
emulsion, more preferably about 0.01 to about 0.05 g/100 mL emulsion, most preferably about 0.014 g/100 mL emulsion.
WO 99/15152 PC1'/US98/19119 Finally, sodium hydroxide can be added to titrate the emulsion to a final pH
of about 8.3 to about 8.8. This pH range is chosen to optimize emulsion stability in the presence of non-buffered saline which is slightly acidic.
In order to manufacture the present invention, a mixture of water-for-injection with the ingredients listed above in the amounts described can be passed through a high pressure hornogenizer. The resulting mixture is an opaque white, milky liquid that is a suspen.~ion of small oil droplets in water, with a normal droplet size distribution. The droplet size has a mean of about 0. 4 ~cm and a maximum of about 4 ~cm. The distribution includes 90% of droplets less than about 0.65 ,um and less than 0.5% of droplets greater than l~cm. Even after experiencing high shear, all droplets remain less than about S,um.
The lubricant is to be shipped in sterile vials and injected into a sterile saline intravenous (I~ bag prior to use. During a rotational atherectomy procedure, the lubricant can be izifused through the catheter of a Rotablator system and then into the coronary artery. Because the present invention is safe for parenteral use, it is a potential lubricant for any device operating inside the human body. Examples of this are: interoperative milk into which endoscopic equipment is dipped before placement into the human body; coating for sutures in order to reduce friction;
lubricant for heart valves in order to ease placement during surgery; lubricant for ultrasonic catheters;
and lubricant for other firture devices that employ swiftly-moving parts within the body.
Experimental Results Sample Preparation Four one-liter lots of 20% olive oil emulsion were prepared, with each 100 mL
of emulsion containing: 20.0 g olive oil, 1.2 g egg yolk phospholipid (a surfactant), 0..40 g sodium deoxycholate (a bile salt co-surfactant), 0.16 g L-histidine (an amino acid pH buffer) , and 0. 0 14 g disodium EDTA (a preservative). 3.0 mEq/L NaOH
was also added to adjust pH. The four lots varied only in glycerin content (a cryogenic agent) in the amounts specified in Table 1. Intralipid, a commercially available lipid emulsion for parenteral nutrition, is included in Tabie 1 for comparison.
Intralipid 20% contains 20% w/v soybean oil, egg yolk phospholipids, glycerin, sodium hydroxide, and water for injection (WFI).
Table 1 Gl~yzerin Concentration Osmolal~ and Zeta Potential Lot Number Glycerin Osmolality, Zeta Potential, Conc., grams/100mOsm/kg my mL
Intrali id 20% 2.25 350* -38 HT-049 1.6 280 -46 HT-050 10.0 300 -48 HT-051 20.0 322 -44 HT-052 30.0 346 -40 *undiluted sample High glycerin concentrations are expected to elevate osmolality and depress the freezing point. The original formulation was designed with 1.6% glycerin to produce an isotonic product, having about 280-320 mOsm/kg. As osmolality could not be measured directly in higher concentration glycerin samples using the freezing point depression method, osmolality was measured after a 1:50 dilution in 0.9%
saline. This dilution was chosen to represent expected clinical practice. The osmolality of the Intralipid was measured on an undiluted sample.
The Zeta potential or net surface charge is an important determinant of stability in colloidal systems. Zeta was calculated from microelectrophoretic mobility in SmM Hepes buffer at pH 8.0 using a laser light scattering detection system (Malvern ZetaSizer). Control (non-frozen) samples were used. As can be seen in Table 1, Zeta potential was most negative at about 10% glycerin concentration.
Visual Inspection At Ieast three separate bottles from each lot were visually inspected for homogeneity and surface oil. Inspections were performed on initial samples about one week after sterilization and on samples that had been subjected to freeze/thaw and shipping. "Creaming" refers to the rapid floatation (e.g.; within an hour) of large, emulsified oil droplets formed either by coalescence or by aggregation of smaller emulsified droplets. In contrast, surface oil ("free oil") droplets are not emulsified.
The results of visual inspection are summarized in Table 2. As can be seen in Table 2, Lot HT-050, having 10% glycerin, had no surface oil and no creaming, either initially or after the freezeJthaw cycle.
Tabte 2 Visual Examination Lot No. Initial (non-frozen)Post Freeze/Tbaw all tem eratures HT-049 no surface oil; no no surface oil; rapid formation creaming of cream la er HT-050 no surface oih no no surface oih no cr creamin HT-051 a few ail droplets a few oil droplets ~1 mm);
(<_1 mm); no no creamin creamin HT-052 no surface oil' no no surface oih no creamin creamin Freeze/Thaw and Stress Testing Measurements of pH and droplet size were performed on triplicate samples from each lot. Test samples were subjected to freeze/thaw and shipping.
Control samples were subjected to no freezing, only shipping. Both control and freezelthaw samples were subjected to a saline/heat/shear stress test. This test involves a 1:20 dilution in 0.9% saline, followed by heating in a 40 degree C water bath for S
minutes, and ending with 3 minute high-shear processing by a rotor-stator device (Ultra Turrax, 20,500 rhm) at 40 degree C. Due to significant deterioration (creaming), freeze/thaw samples from Lot HT-049 (1.6 % glycerin) were not subjected to this test. Some of the data for Intralipid 20% and Lot HT-050 (10% glycerin) are summarized in Table 3.
Table 3 contains the results: pH (before and after freeze/thaw for Lot HT-050); pH after dilution/heat/shear; mean droplet diameter before and after dilution/heat/sheaa-; droplet diameter for which 90% of the droplets have a smaller diameter before and after dilution/heat/shear; droplet diameter for which 100%
of the droplets have a smaller diameter before and after dilution/heat/shear; and the percent of droplets having a droplet diameter greater than 1 micrometer before and after dilution/heatlshear.
Inspection of Table 3 shows a significant increase in droplet diameter after dilution/heatlshear stress for Intralipid 20%. As previously discussed, freezeJthaw of Intralipid 20% results in phase separation. Lot HT-OSO (10% glycerin) in the control (before freeze/thaw) shows a very slight increase in droplet diameter at the 90th percentile and a maximum droplet size of 4.30 micrometers due to dilution/heat/shear.
WO 99/15152 PCT/US98/1.9119 This compares with an Intralipid increase from 0.80 to 1.23 micrometers droplet diameter at the 90th percentile and maximum droplet size of 12.2 micrometers due to dilution/hear/shear. Freezelthaw had an insignificant effect on droplet size for the Lot HT-050 sample. Freeze/thaw also had no significant change on the effects of dilution/heat/shear on the HT-050 sample after thawing.
Table 3 Effects of FreezeJThaw and Heat/Shear on 20% Olive Oil Emulsions Lot pH Heat)Mean Heat!90% Heat/100 Heat/S%<i Heat/
No./Storage ShearDia, Shear<~m Shear%< hear ~m Shear condition pH gum Mean 90% ~m 100% %<i Dia m Intralipid 7.8.56.70 0.49 0.67 0.80 1.23 3.49 12.2 4.6 13.9 %/ Control 50/ Control8.6:37.42 0.40 0.42 0.61 0.65 1.51 4.30 0.50 3.2 50/ Frozen 8.64 7.54 0.40 0.41 0.61 0.64 1.51 4.30 0.50 2.6 Phase-Contrast IyHcroscovv The samples were also observed under phase-contrast microscopy.
Freeze/thaw samples from HT-049 (1.6% glycerin) showed a very large number of coalesced and aggregated oil droplets. In contrast, all elevated glycerin samples, HT-050 (10% glycerin), HT-051 (20% glycerin), and HT-052 (30% glycerin) had a very uniform, clean appearance with no large saline/heat/shear stress test.
Samples from all olive oit lots looked excellent, while the Intralipid samples showed many large coalesced droplets.. These observations are consistent with the drop size distribution data shown in Table 3.
Sample Test Summary The addition of glycerin at 10% weight/volume appears sufficient to protect the olive oil emulsions from freeze/thaw damage for at least 48 hours, even at minus 30 degrees. C. In this respect, no advantages were seen with higher concentrations of glycerin. The presence of elevated glycerin concentration had no significant effect on product appearance, pH, drop size distribution or Zeta potential.
In contrast, the 1.6% glycerin sample (HT-049) exhibited severe creaming following freeze/thaw. The complete preservation of emulsion quality during freeze/thaw using only 10% w/v glycerin (e.g., lot #HT-50) was quite surprising and unexpected.
Since samples stored at -30° C appear to be frozen solid, glycerin is not acting as a simple antifreeze agent. Cryopreservation must be occurring by an action at the oil-water interface of the dispersed droplets, i.e., in the phospholipid monolayer.
The addition of each 10% of glycerin, after a 50-fold droplets. Samples were also observed after the dilution in 0.9% saline, adds about a 20 mOsm/kg increment in osmolality. Thus,, even a 30% glycerin emulsion has a diluted osmolality no higher than undiluted Intralipid 20%. Therefore no tonicity problems are expected in clinical applications.
Utili The utility of the invention was tested using the Rotoblator system. This system rotates a 135 cm stainless steel drive coil with an attached diamond coated burr over a 0.009 inch diameter stainless steel guide wire at 180,000 rpm. The system in current use is lubricated during startup with a thin film of HYSTRENE on the guide wire arid throughout the operation by a continuous infusion of normal saline. This allows for efficient operation for only limited duration, as the lubricant washes away and is not replenished, therefore the performance can start to degrade as the device starts operating. Performance degadation can take the form of loss of speed, heat build-up, guide wire wear, drive coil wear, bun wear and reduced axial mobility.
Optimally, for use with the Rotoblater Advancer/guide wire system, the lubricant should withstand high shear stress at 50° C without emulsion degradation.
All emulsion droplets should remain less than 5 micrometers in diameter, even after shear stress associated with use of this device. In addition, a mixture of the emulsion in saline should remain stable after overnight storage at room temperature and be non toxic.
Wear and Speed Stability Test Lubricants were tested using the Rotoblater advancer. An advancer having a 1.75 mm bun was passed through a PTFE tube with a 2.2 mm ID which is wrapped over a pair of mandrels to create a fixed "S" shaped path. The guide wire distal end is placed about 2 inches past the burr and the fixture immersed in a 37° C
waterbath and run for 5 minutes. The lubricants tested included both normal saline and saline mixed with 20 cc per liter of the olive oil emulsion. The advancer speed was recorded and the wear scars on the guide wire wear measured with a Laser Micrometer. With saline alone, average wear was 0.0048 inch compared with only 0.0001 inch wear for saline with the emulsion added. With saline alone, the average speed change was a decrease of 13877 rpm, compared with an average increase of 79 rpm for saline with the emulsion addexi. Thus, both guide wire wear and speed stability improved with the emulsion added.
Tortuous Advance Force Test Another series of tests was performed, similar to the previous study but having a more tortuous path, to simulate the path of a coronary vessel. The burr was advanced and retracted over an "S" shaped bend throughout the 5 minute test.
The test measured the force required to advance and retract the burr, the advancer speed, and the fluid 5 temperature downstream of the burr in the PTFE tube. With saline alone, the rpm decreased by 13,000 rpm compared with an increase of 800 rpm for saline with emulsion. With saline alone, the peak fluid temperature was 58 degrees C
compared with 47.5 degrees C for saline with emulsion. With saline alone, 170 gm of force was required at the peak to advance the device, compared with 120 gm for saline with emulsi~~on. Thus, the emulsion provided improved lubrication over saline alone.
Comparison with Other Lipid Emulsions Another study was performed using stainless steel rods with surface speeds and pressures similar to those found in the Rotoblater. A series of emulsions of olive oil and Intralipid was tested for wear resistance and emulsion stability. The average wear scars using Intralipid were 64 millionths of an inch +/- 16, compared to only 5 millionths of an inch +/- 11 for olive oil emulsions. Furthermore, the olive oil emulsion showed insignificant post shear changes in droplet size distribution, the mean droplet diameter remaining about 0.4 micrometers. In distinct contrast, the Intralipid lubricant showed a dramatic degradation in the emulsion, including an increase in maximum droplet diameter to about 10 micrometers, an increase in mean droplet diameter to about 0.8 micrometers, an increase in 90th percentile droplet diameter from about 0.8 micrometers to about 2 micrometers, and a bimodal distribution in droplet diameter, having a second peak at about 2 micrometers.
Oil Emulsions Comparison Tests A series of oil emulsion samples was prepared, all containing 20%
weight/volume o:il, 1.2% egg yolk phospholipid, 0.16% L-histidine {10 mM), and 0.014% disodiurn EDTA (0.5 mM). Additional excipients in each sample are indicated in Table 4. Emulsions were prepared by ultrasonic processing (Sonics and Materials Inc., la mm horn, 200 mL sample volume, and 80% power for 15 minutes at 50% duty cycl.e). Drop size distribution was determined by laser light scattering (Malvern MasterSizer). Stainless steel wear testing was expressed as a ratio of WO 99/i5152 PCT/US98/19119 stainless steel volume lost with a saline control divided by the volume lost with the test emulsion. I~gher ratios indicate less steel lost and therefore better lubrication.
Table 4 Olive Oil-in-Water Emulsion is MQSt Effective for Lubrication 5' Prep Oil P6aae,Aqueous Sterile Mean '/a 1 Stainless No. ~Cm 20% w/v .!ldditivepH Dia, Sted ~tm % w/v War, Saline Emulsion 1 MC7.' none 8.14 1.10 18.4 1.09 2 MC7.' glycerin 8.25 0.95 16.8 1.56 2.25%
3 MC7.' PEG 400, 8.21 0.87 18.8 0.95 4 MCT Pluronic 8.24 0.49 4.2 1.88 F68, 1.0%
10 15% :Done 8.11 0.75 18.4 2.53 MC7C 5%
Castor Oil 6 Olive none 8.20 0.65 13.0 23.71 9 SBO~ none 8.25 0.81 25.6 7.12 As can b~e seen from inspection of Table 4, there was a dramatic and unexpected advantage with respect to lubrication efficiency using purified olive oil (Croda) as the emulsified lipid phase versus other oils such as MCT (medium chain triglycerides). Other studies (not shown) confirmed the superiority of olive oil.
Co-surfactant Emulsion Stability Test In order to be useful as a lubricant emulsion, the injectable product must be stable for several hours after dilution in unbuffered, normal, 0.9% saline solution.
Therefore, a series of samples having various aqueous co-surfactants was tested in a 20% olive oil emulsion. The samples included a control having no co-surfactant, PEG-400 added at 5%, Pluronic F68 (nonionic block copolymer) added at 1%, sodium deoxycholate (a bile salt) added at 0.2%, and Intralipid 20%. The emulsions were diluted 1:20 in 0.9% saline and allowed to stand overnight at room temperature.
Emulsion quality was scared by monitoring the formation of large droplets (% >
micrometer) using a laser light scattering instrument. In decreasing order of the percentage of droplets having a diameter greater than 1 micrometer, Intralipid had 60%, Pluroruc F68 42%, PEG-400 37%, control 25%, and deoxycholate 6%.
From several experiments such as this, we concluded that the use of deoxycholate as a co-surfactant best protects this olive oil emulsion following saline dilution.
Diluted Intralipid Droplet Size Tests Intralipid was evaluated for use as a lubricant in a stainless steel wear test.
Intralipid was evaluated after dilution in Water For Injection (WFI), after dilution 1:20 in saline, and after dilution in saline with heat/shear stress.
The initial Intralipid mean droplet diameter after dilution in WFI was 0.44 micrometer, compared with 2.07 after dilation in saline and 0.96 after dilution in saline with heat/shear stress.
The initial percentage of droplets greater than 1 micrometer in diameter was 2.6%, compared with 42..8% after dilution in saline and 26.1% after dilution in saline with heat/shear stress. While Intralipid is a safe and clinically acceptable intravenous nutrition product, it is not useful as an injectable lubricant because this soybean oil emulsion shows large oil droplets and creaming following saline dilution/heat/shear stress.
Ca-surfactant Saline Dilution/Heat/Shear Stress Tests The percentage of large (greater than 1 micrometer droplets, both initially and after saline dilution/heat/stress testing, was measured for emulsions having a series of co-surfactants. Dimyristoylphosphatidylglycerin (DMPG), a charged lipid, was added at 0.2%. Poloxa~ner 331, a lipophilic, non-ionic block copolymer, as added along with DMPG in another sample. Deoxycholate, a bile acid, was added at 0.4%.
Poloxamer 331 was added along with deoxycholate in another sample. Intralipid was also tested.
The DNIPG preparation initially had about 37% of droplets with a diameter greater than 1 micrometer, deoxycholate about 14%, poloxamer/deoxycholate and Intralipid about 3°.~0, and poloxamer/DMPG about 2%. The failure of DMPG to cause smaller droplet size was unexpected since this lipid enhances the stabilizing electronegative surface charge on dispersed droplets.
After saline dilution/heat/stress testing, however; DMPG had about 37% of droplets with a diameter greater than 1 micrometer, poloxamer/deoxycholate about 32%, Intralipid and poloxamer/DMPG about 27% and deoxycholate about 15%.
Thus, while some: co-surfactants provide a finer initial droplet size distribution than deoxycholate, they provide much less protection against saline dilution/heat/shear stress. From studies such as these, we concluded that sodium deoxycholate is the most preferred co-surfactant.
Numerous characteristics and advantages of the invention covered by this document have been set faith in the foregoing description. It will be understood, however, that this disclosure is, in many respects, only illustrative. The scope of this invention is, of caurse, defined in the language in which the appended claims are expressed.
What would be desirable is an improved, pharmacologically compatible medical lubricant. What has not been provided is an injectable medical lubricant suitable for lubricating rotating and otherwise moving medical devices.
Summar~r of the Invention The present inventian includes a medical lubricant suitable for injection into a patient. The lubri<;ant is an oil-in-water emulsion including an oil, a surfactant, a co-surfactant and water. The lubricant preferably also includes a cryogenic agent, a pH
buffer, and a pre.~ervative. The lipid emulsion preferably has a mean particle or droplet diameter of less then 1 micrometer, most preferably less than about 0.5 micrometer. 'Che lubricant can be subjected to substantial shear by a rotating member, exhibits a commercially acceptable shelf life during storage under ambient temperatures, and is able to withstand freeze-thaw cycles without substantial degradation. The lubricant can be diluted in physiological saline for injection and maintains suitable emulsion droplet size after such dilution.
The oil can be a vegetable oil or a medium chain triglyceride. The preferred oil is refined olive oil, which preferably comprises mostly mono-unsaturated oleic acid. The oil can lubricate medical devices such as rotating drive shafts in atherectomy devices, thereby reducing wear on moving parts. A mean droplet size of less than about 1 micrometer allows injection into the bloodstream and subsequent absorption by the body without ill effect. The emulsion most preferably includes about 20 g refined olive oil per 100 mL emulsion.
The surfactant can be a phospholipid, preferably purified egg yolk phospholipids. The surfactant stabilizes the oil droplets dispersed in the continuous aqueous phase. The present invention preferably includes about 1.2 g egg yolk phospholipids per 100 mL emulsion.
The co-surfactant can he a salt of a bile acid, most preferably sodium deoxycholate. The co-surfactant significantly improves droplet stability after saline dilution, heating, and exposure to high shear forces. Droplet stability includes the resistance to forn.~ation of larger droplets, creaming, and formation of a separate oil layer. Bile salt, acting in conjunction with glycerin, provides improved freeze-thaw stability. Applicants believe the bile salt also improves lubricity by acting as a wetting agent, improving 'the coating of moving metal parts. The present invention most preferably includes, about 0.,4 g bile salt per 100 mL emulsion.
The . cryogenic agent can be refined propylene glycol or glycerin, preferably glycerin. glycerin also provides improved lubricity. The present invention preferably includes about 10 g glycerin per 100 mL emulsion.
The pH buffer is preferably an amino acid buffer. The pH buffer imparts improved droplet stability in a saline diluent. The amino acid buffer is most preferably L-histidine in a concentration of about 0.16 g per 100 mL emulsion.
The preservative is preferably a heavy metal chelator such as disodium EDTA
EDTA, and the histidine buffer, serve as antioxidants, protecting unsaturated fatty acids found in egg yolk phospholipids. The antioxidants provide an extended shelf life for the emulsion at room 'temperature and inhibit peroxide formation during clinical use. Disodium EL>TA is preferably present in about 0.014 g per 100 mL
emulsion.
The emulsion preferably has the pH adjusted to between about 8.3 and 8.8 with a base such as sodium. hydroxide. This pH range optimizes the emulsion stability in the presence of non-buffered saline, which is slightly acidic. Sodium hydroxide can be present in about 3.0 mEq per liter of emulsion.
An emulsion according to the present invention can be prepared by combining refined olive oil, 1.2% egg yolk phospholipid, 0.16% L-histidine (IOmIVn, 0.014%
disodium EDTA (~0.5 mlVn, and water, followed by ultrasonic processing for about 15 minutes. The emulsion can also be prepared using high pressure homogenization techniques well known to those skilled in the art.
In use, the: emulsion can be stored for at least 18 months, preferably twenty-four (24) months at room temperature. The emulsion can be stored frozen at minus 30 degrees C, and then thawed without causing significant changes in droplet size distribution. The emulsion can be added to normal, unbuffered 0.9% saline solution. One anticipated use is injection of the emulsion into an IV bag of saline, thereby diluting the emulsion. The diluted emulsion can be infused from the IV
bag through a catheter tube housing a rotating member such as an atherectomy drive shaft or an ultrasonic probe drive shaft. The emulsion serves to lubricate the moving parts and can thereafter enter the blood stream of a patient without ill effect.
WO 99/15152 PG'T/US98/19119 yetailed Description of the Preferred Embodiment In a prefewed embodiment of the invention, the oil-in-water emulsion lubricant comprises a mixture of water, oil, a surfactant, a co-surfactant, a phospholipid, a cryogenic agent, a pH buffer and a preservative.
' Preferably the oil used in the lipid emulsion lubricant is a liquid at room temperature, most preferably olive oil. Chemically, olive oil contains mostly mono-unsaturated oleic acid. Different oil bases, such as either soybean oil, which contains a mixture of polyunsaturated fatty acids, mainly Ci4, C16 and Cig, or medium chain triglycerides {MC'.C) may also be used, especially with varying concentrations of the other ingredients ;and with different surfactants. Almond oil, cocorntt oil, corn oil, cotton seed oil, marine oil, palm kernel oil, peanut oil, safflower oil, sesame oil, sunflower oil, and physical or interesterified mixtures thereof can also be used. These other oil bases, however, are not as effective as olive oil. Quite surprisingly, we found that olive oil emulsions lubricate better than soybean oil emulsions.
The 1 S lubricant reduces wear on moving components. In a preferred embodiment of the invention, the concentratian of olive oil in the lubricant is from about 5 to about 40 g/100 mL emulsion, more preferably about 15 to about 25 g/100 mL emulsion, and is most preferably about 2G g/100 mL emulsion.
An emulsion is a dispersion of one immiscible liquid within another, commonly oil-in-water. An emulsifier is a surface active agent designed to coat and stabilize the dispersed droplets against coalescence. However, in certain formulations, this dispersion is insufficiently stabilized by the primary emulsifier which is typically added at concentrations of about 1-5% w/v. In such cases, a second surface active agent, known as a co-surfactant, may be added. A co-surfactant is typically used at a fractional concenlxadon of the primary emulsifier, e.g., 0.1-1.0%. In principle, co surfactants are added to accomplish specific tasks such as enhancing electrostatic surface charge on the dispersed droplets or strengthening the interfacial film between oil and water. In reality, it is quite difficult to predict in advance which co-surfactant, if any, will stabilize a novel emulsion formulation under specific environmental conditions.
A primary emulsifier in the lipid emulsion lubricant could, for example, be selected from a group of phospholipids such as soy bean or egg yolk phospholipids.
A preferred phospholipid is egg yolk phospholipid, preferably present in a concentration of about 0.3 to about 3 g/100 mL emulsion, more preferably about 0.6 to about 1.8 g/10~D mL emulsion, most preferably about 1.2 g/100 mL emulsion.
The co-surfactant could be, for example, PEG-400 (polyethylene glycol), Pluronic F68 (a nonionic, polyoxethylene-polyoxypropylene block copolymer, BASF) dimyristyl phosphatidyl glycerin (DMPG) , or the salt of a bile acid. When PEG-is used, it can be present at about 5%, we:ight/volume. When Pluronic F68 is used, it can be present at about 1%, weight/volume. Preferably, the co-surfactant is the salt of a bile acid such as cholic acid, deoxycholic acid, taurocholic acid or nnixtures thereof. Most preferably, the co-surfactant is sodium de:oxycholate, as it is somewhat more effective in reducing wear than DMPG. in the present invention, the superiority of sodium deox,/cholate over other tested co-surfactants was unexpected and unpredicted. In a preferred embodiment, sodium deoxycholate is present at a concentration of about 0.04 to about 4 g/100 mL emulsion, more preferably about 0.2 to about 0.8 g/100 mL emulsion, most preferably about 0.4 g/100 mL emulsion.
A preferred cryogenic agent is refined propylene glycol or glycerin, most preferably glycervi. glycerin serves to provide freeze tolerance and improves the overall lubricating properties of the emulsion. glycerin is preferably present at a concentration of about 1 to about 30 g/100 mI, emulsion, more preferably about 2 to about 20 g/100 niL emulsion, most preferably about 10 g/100 mL emulsion.
A preferred pH buffer is an amino acid buffer, for example, alanine, aspartic acid, glycine, histiidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, valine or mixtures thereof. A preferred amino acid buffer is histidine.
I~stidine contributes significant pH buffering capacity in the critical pH 6 to 8 range, having a pKa, of about 6Ø This pH buffering contributes to emulsion stability after dilution in saline. In addition, histidine serves as an antioxidant, specifically a hydroxy radical scavenger. Histidine is preferably present at a concentration of about 0.01 to about 1 g/100 mL emulsion, mare preferably about 0.05 to about 0.3 g/100 mL
emulsion, most preferably about O.lti g/100 mL emulsion.
A preferred preservative is a heavy metal chelator such as disodium EDTA.
The combination of EDT'A and histidine serves as a potent antioxidant to protect unsaturated fatty acids found in egg yolk phospholipids. This antioxidant system serves both to protect the emulsion in the bottle during prolonged storage at room temperature as v~rell as to inhibit peroxide formation during clinical use.
Disodium EDTA is preferably present at a concentration of about 0.001 to about 0.1 g/100 mL
emulsion, more preferably about 0.01 to about 0.05 g/100 mL emulsion, most preferably about 0.014 g/100 mL emulsion.
WO 99/15152 PC1'/US98/19119 Finally, sodium hydroxide can be added to titrate the emulsion to a final pH
of about 8.3 to about 8.8. This pH range is chosen to optimize emulsion stability in the presence of non-buffered saline which is slightly acidic.
In order to manufacture the present invention, a mixture of water-for-injection with the ingredients listed above in the amounts described can be passed through a high pressure hornogenizer. The resulting mixture is an opaque white, milky liquid that is a suspen.~ion of small oil droplets in water, with a normal droplet size distribution. The droplet size has a mean of about 0. 4 ~cm and a maximum of about 4 ~cm. The distribution includes 90% of droplets less than about 0.65 ,um and less than 0.5% of droplets greater than l~cm. Even after experiencing high shear, all droplets remain less than about S,um.
The lubricant is to be shipped in sterile vials and injected into a sterile saline intravenous (I~ bag prior to use. During a rotational atherectomy procedure, the lubricant can be izifused through the catheter of a Rotablator system and then into the coronary artery. Because the present invention is safe for parenteral use, it is a potential lubricant for any device operating inside the human body. Examples of this are: interoperative milk into which endoscopic equipment is dipped before placement into the human body; coating for sutures in order to reduce friction;
lubricant for heart valves in order to ease placement during surgery; lubricant for ultrasonic catheters;
and lubricant for other firture devices that employ swiftly-moving parts within the body.
Experimental Results Sample Preparation Four one-liter lots of 20% olive oil emulsion were prepared, with each 100 mL
of emulsion containing: 20.0 g olive oil, 1.2 g egg yolk phospholipid (a surfactant), 0..40 g sodium deoxycholate (a bile salt co-surfactant), 0.16 g L-histidine (an amino acid pH buffer) , and 0. 0 14 g disodium EDTA (a preservative). 3.0 mEq/L NaOH
was also added to adjust pH. The four lots varied only in glycerin content (a cryogenic agent) in the amounts specified in Table 1. Intralipid, a commercially available lipid emulsion for parenteral nutrition, is included in Tabie 1 for comparison.
Intralipid 20% contains 20% w/v soybean oil, egg yolk phospholipids, glycerin, sodium hydroxide, and water for injection (WFI).
Table 1 Gl~yzerin Concentration Osmolal~ and Zeta Potential Lot Number Glycerin Osmolality, Zeta Potential, Conc., grams/100mOsm/kg my mL
Intrali id 20% 2.25 350* -38 HT-049 1.6 280 -46 HT-050 10.0 300 -48 HT-051 20.0 322 -44 HT-052 30.0 346 -40 *undiluted sample High glycerin concentrations are expected to elevate osmolality and depress the freezing point. The original formulation was designed with 1.6% glycerin to produce an isotonic product, having about 280-320 mOsm/kg. As osmolality could not be measured directly in higher concentration glycerin samples using the freezing point depression method, osmolality was measured after a 1:50 dilution in 0.9%
saline. This dilution was chosen to represent expected clinical practice. The osmolality of the Intralipid was measured on an undiluted sample.
The Zeta potential or net surface charge is an important determinant of stability in colloidal systems. Zeta was calculated from microelectrophoretic mobility in SmM Hepes buffer at pH 8.0 using a laser light scattering detection system (Malvern ZetaSizer). Control (non-frozen) samples were used. As can be seen in Table 1, Zeta potential was most negative at about 10% glycerin concentration.
Visual Inspection At Ieast three separate bottles from each lot were visually inspected for homogeneity and surface oil. Inspections were performed on initial samples about one week after sterilization and on samples that had been subjected to freeze/thaw and shipping. "Creaming" refers to the rapid floatation (e.g.; within an hour) of large, emulsified oil droplets formed either by coalescence or by aggregation of smaller emulsified droplets. In contrast, surface oil ("free oil") droplets are not emulsified.
The results of visual inspection are summarized in Table 2. As can be seen in Table 2, Lot HT-050, having 10% glycerin, had no surface oil and no creaming, either initially or after the freezeJthaw cycle.
Tabte 2 Visual Examination Lot No. Initial (non-frozen)Post Freeze/Tbaw all tem eratures HT-049 no surface oil; no no surface oil; rapid formation creaming of cream la er HT-050 no surface oih no no surface oih no cr creamin HT-051 a few ail droplets a few oil droplets ~1 mm);
(<_1 mm); no no creamin creamin HT-052 no surface oil' no no surface oih no creamin creamin Freeze/Thaw and Stress Testing Measurements of pH and droplet size were performed on triplicate samples from each lot. Test samples were subjected to freeze/thaw and shipping.
Control samples were subjected to no freezing, only shipping. Both control and freezelthaw samples were subjected to a saline/heat/shear stress test. This test involves a 1:20 dilution in 0.9% saline, followed by heating in a 40 degree C water bath for S
minutes, and ending with 3 minute high-shear processing by a rotor-stator device (Ultra Turrax, 20,500 rhm) at 40 degree C. Due to significant deterioration (creaming), freeze/thaw samples from Lot HT-049 (1.6 % glycerin) were not subjected to this test. Some of the data for Intralipid 20% and Lot HT-050 (10% glycerin) are summarized in Table 3.
Table 3 contains the results: pH (before and after freeze/thaw for Lot HT-050); pH after dilution/heat/shear; mean droplet diameter before and after dilution/heat/sheaa-; droplet diameter for which 90% of the droplets have a smaller diameter before and after dilution/heat/shear; droplet diameter for which 100%
of the droplets have a smaller diameter before and after dilution/heat/shear; and the percent of droplets having a droplet diameter greater than 1 micrometer before and after dilution/heatlshear.
Inspection of Table 3 shows a significant increase in droplet diameter after dilution/heatlshear stress for Intralipid 20%. As previously discussed, freezeJthaw of Intralipid 20% results in phase separation. Lot HT-OSO (10% glycerin) in the control (before freeze/thaw) shows a very slight increase in droplet diameter at the 90th percentile and a maximum droplet size of 4.30 micrometers due to dilution/heat/shear.
WO 99/15152 PCT/US98/1.9119 This compares with an Intralipid increase from 0.80 to 1.23 micrometers droplet diameter at the 90th percentile and maximum droplet size of 12.2 micrometers due to dilution/hear/shear. Freezelthaw had an insignificant effect on droplet size for the Lot HT-050 sample. Freeze/thaw also had no significant change on the effects of dilution/heat/shear on the HT-050 sample after thawing.
Table 3 Effects of FreezeJThaw and Heat/Shear on 20% Olive Oil Emulsions Lot pH Heat)Mean Heat!90% Heat/100 Heat/S%<i Heat/
No./Storage ShearDia, Shear<~m Shear%< hear ~m Shear condition pH gum Mean 90% ~m 100% %<i Dia m Intralipid 7.8.56.70 0.49 0.67 0.80 1.23 3.49 12.2 4.6 13.9 %/ Control 50/ Control8.6:37.42 0.40 0.42 0.61 0.65 1.51 4.30 0.50 3.2 50/ Frozen 8.64 7.54 0.40 0.41 0.61 0.64 1.51 4.30 0.50 2.6 Phase-Contrast IyHcroscovv The samples were also observed under phase-contrast microscopy.
Freeze/thaw samples from HT-049 (1.6% glycerin) showed a very large number of coalesced and aggregated oil droplets. In contrast, all elevated glycerin samples, HT-050 (10% glycerin), HT-051 (20% glycerin), and HT-052 (30% glycerin) had a very uniform, clean appearance with no large saline/heat/shear stress test.
Samples from all olive oit lots looked excellent, while the Intralipid samples showed many large coalesced droplets.. These observations are consistent with the drop size distribution data shown in Table 3.
Sample Test Summary The addition of glycerin at 10% weight/volume appears sufficient to protect the olive oil emulsions from freeze/thaw damage for at least 48 hours, even at minus 30 degrees. C. In this respect, no advantages were seen with higher concentrations of glycerin. The presence of elevated glycerin concentration had no significant effect on product appearance, pH, drop size distribution or Zeta potential.
In contrast, the 1.6% glycerin sample (HT-049) exhibited severe creaming following freeze/thaw. The complete preservation of emulsion quality during freeze/thaw using only 10% w/v glycerin (e.g., lot #HT-50) was quite surprising and unexpected.
Since samples stored at -30° C appear to be frozen solid, glycerin is not acting as a simple antifreeze agent. Cryopreservation must be occurring by an action at the oil-water interface of the dispersed droplets, i.e., in the phospholipid monolayer.
The addition of each 10% of glycerin, after a 50-fold droplets. Samples were also observed after the dilution in 0.9% saline, adds about a 20 mOsm/kg increment in osmolality. Thus,, even a 30% glycerin emulsion has a diluted osmolality no higher than undiluted Intralipid 20%. Therefore no tonicity problems are expected in clinical applications.
Utili The utility of the invention was tested using the Rotoblator system. This system rotates a 135 cm stainless steel drive coil with an attached diamond coated burr over a 0.009 inch diameter stainless steel guide wire at 180,000 rpm. The system in current use is lubricated during startup with a thin film of HYSTRENE on the guide wire arid throughout the operation by a continuous infusion of normal saline. This allows for efficient operation for only limited duration, as the lubricant washes away and is not replenished, therefore the performance can start to degrade as the device starts operating. Performance degadation can take the form of loss of speed, heat build-up, guide wire wear, drive coil wear, bun wear and reduced axial mobility.
Optimally, for use with the Rotoblater Advancer/guide wire system, the lubricant should withstand high shear stress at 50° C without emulsion degradation.
All emulsion droplets should remain less than 5 micrometers in diameter, even after shear stress associated with use of this device. In addition, a mixture of the emulsion in saline should remain stable after overnight storage at room temperature and be non toxic.
Wear and Speed Stability Test Lubricants were tested using the Rotoblater advancer. An advancer having a 1.75 mm bun was passed through a PTFE tube with a 2.2 mm ID which is wrapped over a pair of mandrels to create a fixed "S" shaped path. The guide wire distal end is placed about 2 inches past the burr and the fixture immersed in a 37° C
waterbath and run for 5 minutes. The lubricants tested included both normal saline and saline mixed with 20 cc per liter of the olive oil emulsion. The advancer speed was recorded and the wear scars on the guide wire wear measured with a Laser Micrometer. With saline alone, average wear was 0.0048 inch compared with only 0.0001 inch wear for saline with the emulsion added. With saline alone, the average speed change was a decrease of 13877 rpm, compared with an average increase of 79 rpm for saline with the emulsion addexi. Thus, both guide wire wear and speed stability improved with the emulsion added.
Tortuous Advance Force Test Another series of tests was performed, similar to the previous study but having a more tortuous path, to simulate the path of a coronary vessel. The burr was advanced and retracted over an "S" shaped bend throughout the 5 minute test.
The test measured the force required to advance and retract the burr, the advancer speed, and the fluid 5 temperature downstream of the burr in the PTFE tube. With saline alone, the rpm decreased by 13,000 rpm compared with an increase of 800 rpm for saline with emulsion. With saline alone, the peak fluid temperature was 58 degrees C
compared with 47.5 degrees C for saline with emulsion. With saline alone, 170 gm of force was required at the peak to advance the device, compared with 120 gm for saline with emulsi~~on. Thus, the emulsion provided improved lubrication over saline alone.
Comparison with Other Lipid Emulsions Another study was performed using stainless steel rods with surface speeds and pressures similar to those found in the Rotoblater. A series of emulsions of olive oil and Intralipid was tested for wear resistance and emulsion stability. The average wear scars using Intralipid were 64 millionths of an inch +/- 16, compared to only 5 millionths of an inch +/- 11 for olive oil emulsions. Furthermore, the olive oil emulsion showed insignificant post shear changes in droplet size distribution, the mean droplet diameter remaining about 0.4 micrometers. In distinct contrast, the Intralipid lubricant showed a dramatic degradation in the emulsion, including an increase in maximum droplet diameter to about 10 micrometers, an increase in mean droplet diameter to about 0.8 micrometers, an increase in 90th percentile droplet diameter from about 0.8 micrometers to about 2 micrometers, and a bimodal distribution in droplet diameter, having a second peak at about 2 micrometers.
Oil Emulsions Comparison Tests A series of oil emulsion samples was prepared, all containing 20%
weight/volume o:il, 1.2% egg yolk phospholipid, 0.16% L-histidine {10 mM), and 0.014% disodiurn EDTA (0.5 mM). Additional excipients in each sample are indicated in Table 4. Emulsions were prepared by ultrasonic processing (Sonics and Materials Inc., la mm horn, 200 mL sample volume, and 80% power for 15 minutes at 50% duty cycl.e). Drop size distribution was determined by laser light scattering (Malvern MasterSizer). Stainless steel wear testing was expressed as a ratio of WO 99/i5152 PCT/US98/19119 stainless steel volume lost with a saline control divided by the volume lost with the test emulsion. I~gher ratios indicate less steel lost and therefore better lubrication.
Table 4 Olive Oil-in-Water Emulsion is MQSt Effective for Lubrication 5' Prep Oil P6aae,Aqueous Sterile Mean '/a 1 Stainless No. ~Cm 20% w/v .!ldditivepH Dia, Sted ~tm % w/v War, Saline Emulsion 1 MC7.' none 8.14 1.10 18.4 1.09 2 MC7.' glycerin 8.25 0.95 16.8 1.56 2.25%
3 MC7.' PEG 400, 8.21 0.87 18.8 0.95 4 MCT Pluronic 8.24 0.49 4.2 1.88 F68, 1.0%
10 15% :Done 8.11 0.75 18.4 2.53 MC7C 5%
Castor Oil 6 Olive none 8.20 0.65 13.0 23.71 9 SBO~ none 8.25 0.81 25.6 7.12 As can b~e seen from inspection of Table 4, there was a dramatic and unexpected advantage with respect to lubrication efficiency using purified olive oil (Croda) as the emulsified lipid phase versus other oils such as MCT (medium chain triglycerides). Other studies (not shown) confirmed the superiority of olive oil.
Co-surfactant Emulsion Stability Test In order to be useful as a lubricant emulsion, the injectable product must be stable for several hours after dilution in unbuffered, normal, 0.9% saline solution.
Therefore, a series of samples having various aqueous co-surfactants was tested in a 20% olive oil emulsion. The samples included a control having no co-surfactant, PEG-400 added at 5%, Pluronic F68 (nonionic block copolymer) added at 1%, sodium deoxycholate (a bile salt) added at 0.2%, and Intralipid 20%. The emulsions were diluted 1:20 in 0.9% saline and allowed to stand overnight at room temperature.
Emulsion quality was scared by monitoring the formation of large droplets (% >
micrometer) using a laser light scattering instrument. In decreasing order of the percentage of droplets having a diameter greater than 1 micrometer, Intralipid had 60%, Pluroruc F68 42%, PEG-400 37%, control 25%, and deoxycholate 6%.
From several experiments such as this, we concluded that the use of deoxycholate as a co-surfactant best protects this olive oil emulsion following saline dilution.
Diluted Intralipid Droplet Size Tests Intralipid was evaluated for use as a lubricant in a stainless steel wear test.
Intralipid was evaluated after dilution in Water For Injection (WFI), after dilution 1:20 in saline, and after dilution in saline with heat/shear stress.
The initial Intralipid mean droplet diameter after dilution in WFI was 0.44 micrometer, compared with 2.07 after dilation in saline and 0.96 after dilution in saline with heat/shear stress.
The initial percentage of droplets greater than 1 micrometer in diameter was 2.6%, compared with 42..8% after dilution in saline and 26.1% after dilution in saline with heat/shear stress. While Intralipid is a safe and clinically acceptable intravenous nutrition product, it is not useful as an injectable lubricant because this soybean oil emulsion shows large oil droplets and creaming following saline dilution/heat/shear stress.
Ca-surfactant Saline Dilution/Heat/Shear Stress Tests The percentage of large (greater than 1 micrometer droplets, both initially and after saline dilution/heat/stress testing, was measured for emulsions having a series of co-surfactants. Dimyristoylphosphatidylglycerin (DMPG), a charged lipid, was added at 0.2%. Poloxa~ner 331, a lipophilic, non-ionic block copolymer, as added along with DMPG in another sample. Deoxycholate, a bile acid, was added at 0.4%.
Poloxamer 331 was added along with deoxycholate in another sample. Intralipid was also tested.
The DNIPG preparation initially had about 37% of droplets with a diameter greater than 1 micrometer, deoxycholate about 14%, poloxamer/deoxycholate and Intralipid about 3°.~0, and poloxamer/DMPG about 2%. The failure of DMPG to cause smaller droplet size was unexpected since this lipid enhances the stabilizing electronegative surface charge on dispersed droplets.
After saline dilution/heat/stress testing, however; DMPG had about 37% of droplets with a diameter greater than 1 micrometer, poloxamer/deoxycholate about 32%, Intralipid and poloxamer/DMPG about 27% and deoxycholate about 15%.
Thus, while some: co-surfactants provide a finer initial droplet size distribution than deoxycholate, they provide much less protection against saline dilution/heat/shear stress. From studies such as these, we concluded that sodium deoxycholate is the most preferred co-surfactant.
Numerous characteristics and advantages of the invention covered by this document have been set faith in the foregoing description. It will be understood, however, that this disclosure is, in many respects, only illustrative. The scope of this invention is, of caurse, defined in the language in which the appended claims are expressed.
Claims (38)
1. A medical lubricant oil emulsion comprising a mixture of:
an oil;
a surfactant;
a co-surfactant;
a pH buffer, wherein when said pH buffer is an amino acid buffer said amino acid buffer having a concentration of less than 0.20 g/100 mL emulsion; and water.
an oil;
a surfactant;
a co-surfactant;
a pH buffer, wherein when said pH buffer is an amino acid buffer said amino acid buffer having a concentration of less than 0.20 g/100 mL emulsion; and water.
2. A medical lubricant as recited in claim 1, wherein said oil comprises at least 60% mixed triglycerides of mono-unsaturated oleic acid, said surfactant is a phospholipid, said co-surfactant is a bile salt, and said pH buffer is an amino acid buffer.
3. A medical lubricant as recited in claim 1, wherein said oil is a vegetable oil.
4. A medical lubricant as recited in claim 3, wherein said vegetable oil is selected from the group of refined oils consisting of almond oil, coconut oil, corn oil, cotton seed oil, marine oil, olive oil, palm kernel oil, peanut oil, safflower oil, sesame oil, soybean oil, sunflower oil, and physical or interesterified mixtures thereof.
5. A medical lubricant as recited in claim 4, wherein said vegetable oil is purified olive oil comprised mostly of triglycerides of mono-unsaturated oleic acid.
6. A medical lubricant as recited in claim 2, wherein said phospholipid is selected from the group consisting of soy bean and egg yolk phospholipids.
7. A medical lubricant as recited in claim 2, wherein said phospholipid is egg yolk phospholipid.
8. A medical lubricant as recited in claim 2, wherein said bile salt is selected from the group of salts of bile acids consisting of cholic acid, deoxycholic acid, glycocholic acid, taurocholic acid, and mixtures thereof.
9. A medical lubricant as recited in claim 8, wherein said bile salt is sodium deoxycholate.
10. A medical lubricant as recited in claim 2, wherein said amino acid buffer is selected from the group consisting of alanine, aspartic acid, glycine, histidine, isoleucine, leucine, methionine, phenylalanine, proline, serine, valine, and mixtures thereof.
11. A medical lubricant as recited in claim 10, wherein said amino acid buffer is L-histidine.
12. A medical lubricant as recited in claim 2, further comprising a cryogenic agent.
13. A medical lubricant as recited in claim 12, wherein said cryogenic agent is glycerin.
14. A medical lubricant as recited in claim 2, further comprising a heavy metal chelator.
15. A medical lubricant as recited in claim 14, wherein said chelator includes a physiologically acceptable salt of ethylenediamine tetracetic acid (EDTA).
16. A medical lubricant oil emulsion comprising:
an oil selected from the group of oils consisting of almond oil, coconut oil, corn oil, cotton seed oil, marine oil, olive oil, palm kernel oil, peanut oil, safflower oil, sesame oil, soybean oil, sunflower oil, and physical or interesterified mixtures thereof;
a phospholipid:
a bile salt;
a cryogenic agent;
an amino acid buffer having a concentration of less than 0.20 g/100 mL
emulsion; and water.
an oil selected from the group of oils consisting of almond oil, coconut oil, corn oil, cotton seed oil, marine oil, olive oil, palm kernel oil, peanut oil, safflower oil, sesame oil, soybean oil, sunflower oil, and physical or interesterified mixtures thereof;
a phospholipid:
a bile salt;
a cryogenic agent;
an amino acid buffer having a concentration of less than 0.20 g/100 mL
emulsion; and water.
17. A medical lubricant as recited in claim 16, wherein said lipid emulsion has a mean droplet size less than about 5 micro meters.
18. A medical lubricant as recited in claim 16, wherein said lipid emulsion has a mean droplet size less than about 1 micro meter.
19. A medical lubricant as recited in claim 17, wherein said lipid has a concentration of between about 5 and about 40 g/100 mL emulsion, said phospholipid includes egg yolk phospholipid and has a concentration of between about 0.3 and about 3 g/100 mL emulsion, said bile salt has a concentration of between about 0.04 and about 4.0 g/100 mL emulsion, said cryogenic agent is selected from the group consisting of refined propylene glycol and glycerin and has a concentration between about 1 and about 30 g/100 mL emulsion, and said amino acid buffer has a concentration of between about 0.01 and 0.19 g/100 mL emulsion.
20. A medical lubricant as recited in claim 19, wherein said lipid includes olive oil and has a concentration of between about 15 and about 25 g/100 mL
emulsion, said phospholipid has a concentration of between about 0.6 and about 1.8 g/100 mL emulsion, said bile salt includes sodium deoxycholate and has a concentration of between about 0.2 and about 0.8 g/100 mL emulsion, said cryogenic: agent includes glycerin and has a concentration between about 2 and about 20 g/100 mL, emulsion, and said amino acid buffer includes L-histidine and has a concentration of between about 0.05 and 0.19 g/100 mL emulsion.
emulsion, said phospholipid has a concentration of between about 0.6 and about 1.8 g/100 mL emulsion, said bile salt includes sodium deoxycholate and has a concentration of between about 0.2 and about 0.8 g/100 mL emulsion, said cryogenic: agent includes glycerin and has a concentration between about 2 and about 20 g/100 mL, emulsion, and said amino acid buffer includes L-histidine and has a concentration of between about 0.05 and 0.19 g/100 mL emulsion.
21. A medical lubricant oil emulsion comprising:
refined olive oil;
egg yolk phospholipid;
sodium deoxycholate;
glycerin;
L-histidine having a concentration of less than 0.20 g/100 mL emulsion; and water for injection.
refined olive oil;
egg yolk phospholipid;
sodium deoxycholate;
glycerin;
L-histidine having a concentration of less than 0.20 g/100 mL emulsion; and water for injection.
22. A medical lubricant as recited in claim 21, further comprising disodium EDTA and sodium hydroxide.
23. A method of lubricating a medical device comprising:
introducing a medical lubricant oil emulsion into a patient during treatment of the patient with a medical device wherein said medical device has a moving part that is operative inside the patient, and contacting said moving part inside the patient with said medical lubricant, said medical lubricant comprising:
a vegetable oil;
a phospholipid;
a bile salt; and water.
introducing a medical lubricant oil emulsion into a patient during treatment of the patient with a medical device wherein said medical device has a moving part that is operative inside the patient, and contacting said moving part inside the patient with said medical lubricant, said medical lubricant comprising:
a vegetable oil;
a phospholipid;
a bile salt; and water.
24. The method of claim 23, wherein the medical lubricant further comprises a pH buffer.
25. The method of claim 23, wherein the medical device is selected from the group consisting of an atherectomy device, an angioplasty devise, a cardiac assist device, an ultrasonic catheter, a minimally invasive surgical devise and a heart valve.
26. The method of claim 24, further comprising diluting the medical lubricant up to two hundred-fold with a suitable solution prior to intravenous infusion.
27. The method of claim 26, further comprising infusing the diluted medical lubricant through a catheter or a catheter housing the medical device.
28. The method of claim 23 wherein said vegetable oil is refined olive oil, said phospholipid is egg yolk phospholipid, said bile salt is sodium deoxycholate, said medical lubricant further comprising:
glycerin;
L-histidine;
disodium ethylenediamine tetracetic acid (EDTA); and sodium hydroxide.
glycerin;
L-histidine;
disodium ethylenediamine tetracetic acid (EDTA); and sodium hydroxide.
29. The method of claim 28, wherein the medical device is selected from the group consisting of an atherectomy device, an angioplasty devise, a cardiac assist device, an ultrasonic catheter, a minimally invasive surgical devise and a heart valve.
30. The method of claim 28, further comprising diluting the medical lubricant up to two hundred-fold with a suitable solution prior to intravenous infusion.
31. The method of claim 30, further comprising infusing the diluted medical lubricant through a catheter or a catheter housing the medical device.
32. A method of lubricating a medical device comprising:
coating a medical device prior to use in a patient with a medical lubricant, said medical lubricant comprising:
an oil;
a phospholipid;
a bile salt; and water, wherein the medical device is selected from the group consisting of a suture material, an endoscopic instrument, an atherectomy device, an angioplasty devise, a cardiac assist device, an ultrasonic catheter, a minimally invasive surgical devise and a heart valve.
coating a medical device prior to use in a patient with a medical lubricant, said medical lubricant comprising:
an oil;
a phospholipid;
a bile salt; and water, wherein the medical device is selected from the group consisting of a suture material, an endoscopic instrument, an atherectomy device, an angioplasty devise, a cardiac assist device, an ultrasonic catheter, a minimally invasive surgical devise and a heart valve.
33. The method of claim 32, wherein the lipid is refined olive oil, the phospholipid is egg yolk phospholipid, the bile salt is sodium deoxycholate, said medical lubricant further comprising:
glycerin;
L-histidine;
disodium ethylenediamine tetracetic acid (EDTA); and sodium hydroxide.
glycerin;
L-histidine;
disodium ethylenediamine tetracetic acid (EDTA); and sodium hydroxide.
34. A method of lubricating an intravascular device comprising:
preparing a patient for atherectomy;
inserting into the patient an intravascular device, said intravascular device capable of differentially removing intravascular deposits from the walls of an artery;
infusing a medical lubricant into the patient during said insertion or during operation of said intravascular device, said medical lubricant oil emulsion comprising:
olive oil;
an egg yolk phospholipid;
a bile salt;
an amino acid buffer; and water.
preparing a patient for atherectomy;
inserting into the patient an intravascular device, said intravascular device capable of differentially removing intravascular deposits from the walls of an artery;
infusing a medical lubricant into the patient during said insertion or during operation of said intravascular device, said medical lubricant oil emulsion comprising:
olive oil;
an egg yolk phospholipid;
a bile salt;
an amino acid buffer; and water.
35. The method of claim 34 wherein said intravascular device is a rotational atherectomy device.
36. The method of claim 34, wherein the medical lubricant oil emulsion further comprises:
a cryogenic agent;
a heavy metal chelating agent; and a pH adjusting base.
a cryogenic agent;
a heavy metal chelating agent; and a pH adjusting base.
37. The method of claim 36, wherein said olive oil has a concentration of between 5 and 40 g/100 mL emulsion, said egg yolk phospholipid has a concentration of between 0.3 and 3 g/100 mL emulsion, said bile salt has a concentration of between 0.04 and 4.0 g/100 mL emulsion, said cryogenic agent has a concentration between 1 and 30 g/100 mL emulsion, said amino acid buffer has a concentration between 0.01 and 1 g/100 mL emulsion, said chelating agent is disodium EDTA having a concentration between 0.005 and 0.05 g/100 mL emulsion, said pH adjusting base is sodium hydroxide and the pH is adjusted to a pH
between 8.3 and 8.8, and said medical emulsion has a mean droplet size of less than micro meters.
between 8.3 and 8.8, and said medical emulsion has a mean droplet size of less than micro meters.
38. The method of claim 37 wherein said intravascular device is a rotational atherectomy device.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/935,698 | 1997-09-23 | ||
| US08/935,698 US6054421A (en) | 1997-09-23 | 1997-09-23 | Medical emulsion lubricant |
| PCT/US1998/019119 WO1999015152A1 (en) | 1997-09-23 | 1998-09-14 | Medical emulsion lubricant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2303888A1 true CA2303888A1 (en) | 1999-04-01 |
Family
ID=25467530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002303888A Abandoned CA2303888A1 (en) | 1997-09-23 | 1998-09-14 | Medical emulsion lubricant |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6054421A (en) |
| EP (1) | EP1024791B1 (en) |
| JP (1) | JP2001517712A (en) |
| CA (1) | CA2303888A1 (en) |
| DE (1) | DE69819551T2 (en) |
| WO (1) | WO1999015152A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6281175B1 (en) | 1997-09-23 | 2001-08-28 | Scimed Life Systems, Inc. | Medical emulsion for lubrication and delivery of drugs |
| US6620852B2 (en) * | 2001-12-17 | 2003-09-16 | Gerald Brogan | Topical anesthetic |
| EP1675908B1 (en) * | 2003-10-07 | 2008-12-17 | Coloplast A/S | Composition useful as an adhesive ans use of such a composition |
| US7235515B2 (en) * | 2004-02-11 | 2007-06-26 | Ibnsina Karkenny | Method of making a lubrication additive |
| US20060127468A1 (en) | 2004-05-19 | 2006-06-15 | Kolodney Michael S | Methods and related compositions for reduction of fat and skin tightening |
| ES2660172T3 (en) * | 2004-05-19 | 2018-03-21 | Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center | Injectable composition comprising sodium deoxycholate |
| US8858608B2 (en) * | 2007-12-10 | 2014-10-14 | Cook Medical Technologies Llc | Lubrication apparatus for a delivery and deployment device |
| EP2300540A4 (en) * | 2008-06-20 | 2012-01-04 | 3M Innovative Properties Co | An aqueous lubricant emulsion for medical or apparatus and a method of washing |
| US8101593B2 (en) | 2009-03-03 | 2012-01-24 | Kythera Biopharmaceuticals, Inc. | Formulations of deoxycholic acid and salts thereof |
| US9011932B2 (en) * | 2010-09-16 | 2015-04-21 | Bausch & Lomb Incorporated | Contact lens care system with peroxide |
| EP2675460A4 (en) | 2011-02-18 | 2014-07-09 | Kythera Biopharmaceuticals Inc | Treatment of submental fat |
| US8653058B2 (en) | 2011-04-05 | 2014-02-18 | Kythera Biopharmaceuticals, Inc. | Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits |
| WO2013125026A1 (en) * | 2012-02-24 | 2013-08-29 | ファインバイオメディカル有限会社 | Lubricant regulating agent |
| CN104940939B (en) * | 2014-06-16 | 2016-11-23 | 沈阳药科大学 | Heavy dose of glycerol application in can tolerate freeze thawing lipomul |
| JP2020059793A (en) * | 2018-10-09 | 2020-04-16 | オリンパス株式会社 | Lubricant for medical equipment and medical equipment |
| WO2023060216A1 (en) * | 2021-10-08 | 2023-04-13 | Bard Peripheral Vascular, Inc. | Biocompatible and allergen free lipid emulsions |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1934100A (en) * | 1933-11-07 | Production of neat s-fooff | ||
| US52301A (en) * | 1866-01-30 | Improved oil for lubricating machinery | ||
| US1525867A (en) * | 1924-01-14 | 1925-02-10 | Koszyczarek Anastaza | Lubricating composition for internal-combustion engines |
| US1857501A (en) * | 1928-09-19 | 1932-05-10 | George F Gallagher | Lubricant |
| US1970902A (en) * | 1931-12-31 | 1934-08-21 | Standard Oil Co | Lubricant |
| US2210043A (en) * | 1938-10-21 | 1940-08-06 | Scherr Samuel | Composition for greasing baking pans and the like |
| US2192866A (en) * | 1939-06-17 | 1940-03-05 | Musher Foundation Inc | Treatment of mineral oil |
| US2487377A (en) * | 1948-04-17 | 1949-11-08 | Socony Vacuum Oil Co Inc | Lubricant |
| US3377276A (en) * | 1963-11-07 | 1968-04-09 | Phillips Petroleum Co | Drilling fluids and additives therefor |
| US4115313A (en) * | 1974-10-08 | 1978-09-19 | Irving Lyon | Bile acid emulsions |
| FR2381558A1 (en) * | 1977-02-23 | 1978-09-22 | Oreal | NEW "WATER-IN-OIL" OR "OIL-IN-WATER" TYPE EMULSIONS AND COSMETIC PRODUCTS OBTAINED WITH THE HELP OF THESE EMULSIONS |
| JPS5810365B2 (en) * | 1978-09-08 | 1983-02-25 | 田辺製薬株式会社 | fat emulsion |
| DE3237814A1 (en) * | 1982-10-12 | 1984-04-12 | Warner-Lambert Co., 07950 Morris Plains, N.J. | WATER-FREE EMULSIONS AND USE THEREOF |
| US4703062A (en) * | 1984-01-16 | 1987-10-27 | Baxter Travenol Laboratories, Inc. | Parenteral nutrition with medium and long chain triglycerides |
| US4567045A (en) * | 1984-01-20 | 1986-01-28 | Kabivitrum Ab | Isotonic glycerol free intravenous fat emulsion |
| US4816247A (en) * | 1985-09-11 | 1989-03-28 | American Cyanamid Company | Emulsion compositions for administration of sparingly water soluble ionizable hydrophobic drugs |
| US4784845A (en) * | 1985-09-16 | 1988-11-15 | American Cyanamid Company | Emulsion compostions for the parenteral administration of sparingly water soluble ionizable hydrophobic drugs |
| US5461037A (en) * | 1985-10-15 | 1995-10-24 | Clintec Nutrition Company | Lipid emulsion |
| CA1293663C (en) * | 1986-01-06 | 1991-12-31 | David Christopher Auth | Transluminal microdissection device |
| US4920098A (en) * | 1986-09-17 | 1990-04-24 | Baxter International Inc. | Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases |
| US5314407A (en) * | 1986-11-14 | 1994-05-24 | Heart Technology, Inc. | Clinically practical rotational angioplasty system |
| AU8114987A (en) * | 1986-11-14 | 1988-05-19 | Heart Technology, Inc. | Clinically practical rotational angioplasty system |
| US5001009A (en) * | 1987-09-02 | 1991-03-19 | Sterilization Technical Services, Inc. | Lubricious hydrophilic composite coated on substrates |
| US5244925A (en) * | 1987-12-18 | 1993-09-14 | Kabi Pharmacia Aktiebolag | Emulsion for parenteral administration |
| US5258184A (en) * | 1988-06-03 | 1993-11-02 | Unilever Patent Holdings B.V. | Emulsions |
| GB8813161D0 (en) * | 1988-06-03 | 1988-07-06 | Unilever Plc | Emulsions |
| US5010067A (en) * | 1988-07-19 | 1991-04-23 | Sandoz Pharmaceuticals Corp. | Triglyceride-water emulsion pharmaceutical vehicles |
| US5041292A (en) * | 1988-08-31 | 1991-08-20 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
| US4925677A (en) * | 1988-08-31 | 1990-05-15 | Theratech, Inc. | Biodegradable hydrogel matrices for the controlled release of pharmacologically active agents |
| EP0361928B1 (en) * | 1988-09-29 | 1994-04-27 | Shiseido Company Limited | Emulsified composition |
| GB8822857D0 (en) * | 1988-09-29 | 1988-11-02 | Patralan Ltd | Pharmaceutical formulations |
| US5171737A (en) * | 1989-03-03 | 1992-12-15 | The Liposome Company, Inc. | Emulsions |
| US5364632A (en) * | 1989-04-05 | 1994-11-15 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Medicinal emulsions |
| CA2013755C (en) * | 1989-04-05 | 1993-11-30 | Simon Benita | Medicinal emulsions |
| JPH0669966B2 (en) * | 1989-07-05 | 1994-09-07 | 株式会社ミドリ十字 | Angiography aid |
| US5089268A (en) * | 1990-05-02 | 1992-02-18 | Katz David P | Egg phosphatide lipid emulsions altered for a specific therapeutic fatty acid composition |
| US5229023A (en) * | 1990-10-12 | 1993-07-20 | International Lubricants, Inc. | Telomerized triglyceride vegetable oil for lubricant additives |
| US5266359A (en) * | 1991-01-14 | 1993-11-30 | Becton, Dickinson And Company | Lubricative coating composition, article and assembly containing same and method thereof |
| US5256422A (en) * | 1991-03-28 | 1993-10-26 | Micro Vesicular Systems, Inc. | Lipid vesicle containing water-in-oil emulsions |
| US5427700A (en) * | 1991-08-09 | 1995-06-27 | The Lubrizol Corporation | Functional fluid with triglycerides, detergent-inhibitor additives and viscosity modifying additives |
| IL101007A (en) * | 1992-02-18 | 1997-08-14 | Pharmos Ltd | Dry stable compositions prepared by lyophilization |
| AU675930B2 (en) * | 1992-02-18 | 1997-02-27 | Pharmos Corp. | Dry compositions for preparing submicron emulsions |
| FR2693470B1 (en) * | 1992-07-07 | 1994-09-23 | Roquette Freres | Compositions for aqueous machining fluids and aqueous machining fluids based on fatty substances and cyclodextrin. |
| US5413725A (en) * | 1992-12-18 | 1995-05-09 | The Lubrizol Corporation | Pour point depressants for high monounsaturated vegetable oils and for high monounsaturated vegetable oils/biodegradable base and fluid mixtures |
| DE4323771A1 (en) * | 1993-07-15 | 1995-01-19 | Henkel Kgaa | Triglyceride-based base oil for hydraulic oils |
| SE9303281D0 (en) * | 1993-10-07 | 1993-10-07 | Astra Ab | New formulation |
| US5338471A (en) * | 1993-10-15 | 1994-08-16 | The Lubrizol Corporation | Pour point depressants for industrial lubricants containing mixtures of fatty acid esters and vegetable oils |
| US5427704A (en) * | 1994-01-28 | 1995-06-27 | The Lubrizol Corporation | Triglyceride oils thickened with estolides of hydroxy-containing triglycerides |
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| PT754032E (en) * | 1994-04-08 | 2002-05-31 | Atrix Lab Inc | LIQUID COMPOSITIONS FOR DIFFUSE |
| CA2153553A1 (en) * | 1994-07-13 | 1996-01-14 | Hidekazu Suzuki | Stable lipid emulsion |
| US5658864A (en) * | 1995-03-24 | 1997-08-19 | Ethyl Corporation | Biodegradable pour point depressants for industrial fluids derived from biodegradable base oils |
| US5616342A (en) * | 1995-04-11 | 1997-04-01 | Pdt, Inc. | Emulsioin suitable for administering a poorly water-soluble photosensitizing compound and use thereof |
| US5728678A (en) * | 1995-06-06 | 1998-03-17 | Nestec Ltd. | Method and composition for providing nutrition to a renal failure patient |
| DE69634442T2 (en) * | 1995-06-06 | 2006-04-13 | Agro Management Group, Inc., Colorado Springs | BIODEGRADABLE LUBRICANT FLUIDS ON PLANT BASIS |
| US5801131A (en) * | 1995-09-29 | 1998-09-01 | Coffey Marketing Corporation | Lubricant composition for musical instruments |
| US5660858A (en) * | 1996-04-03 | 1997-08-26 | Research Triangle Pharmaceuticals | Cyclosporin emulsions |
| US5595965A (en) * | 1996-05-08 | 1997-01-21 | The Lubrizol Corporation | Biodegradable vegetable oil grease |
| US5858934A (en) * | 1996-05-08 | 1999-01-12 | The Lubrizol Corporation | Enhanced biodegradable vegetable oil grease |
| US5736493A (en) * | 1996-05-15 | 1998-04-07 | Renewable Lubricants, Inc. | Biodegradable lubricant composition from triglycerides and oil soluble copper |
| US5703022A (en) * | 1997-01-06 | 1997-12-30 | The Lubrizol Corporation | Sulfurized vegetable oils containing anti-oxidants for use as base fluids |
-
1997
- 1997-09-23 US US08/935,698 patent/US6054421A/en not_active Expired - Lifetime
-
1998
- 1998-09-14 CA CA002303888A patent/CA2303888A1/en not_active Abandoned
- 1998-09-14 EP EP98946997A patent/EP1024791B1/en not_active Expired - Lifetime
- 1998-09-14 DE DE69819551T patent/DE69819551T2/en not_active Expired - Lifetime
- 1998-09-14 JP JP2000512523A patent/JP2001517712A/en not_active Withdrawn
- 1998-09-14 WO PCT/US1998/019119 patent/WO1999015152A1/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2001517712A (en) | 2001-10-09 |
| WO1999015152A1 (en) | 1999-04-01 |
| DE69819551D1 (en) | 2003-12-11 |
| DE69819551T2 (en) | 2004-09-23 |
| EP1024791A1 (en) | 2000-08-09 |
| EP1024791B1 (en) | 2003-11-05 |
| US6054421A (en) | 2000-04-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2404196C (en) | Medical emulsion for lubrication and delivery of drugs | |
| US6054421A (en) | Medical emulsion lubricant | |
| JP6741655B2 (en) | Emulsion formulation of aprepitant | |
| AU2012204932B2 (en) | O/w-emulsions comprising semifluorinated alkanes | |
| EP1545757B1 (en) | Perfluorocarbon emulsions with non-fluorinated surfactants | |
| EP2714010B1 (en) | Topical pharmaceutical composition based on semifluorinated alkanes | |
| JPH03161430A (en) | Emulsified composition | |
| CA2222063A1 (en) | Reverse fluorocarbon emulsion compositions for drug delivery | |
| CA2020368C (en) | Angiographic adjuvant | |
| NO176747B (en) | Iodine-containing emulsion and its use for the preparation of an X-ray contrast agent | |
| WO1997036576A1 (en) | Preparation method of emulsion for chemoembolization | |
| WO1997003644A1 (en) | Reverse gels comprising a continuous fluorinated phase | |
| JPH0442370B2 (en) | ||
| JPS60166626A (en) | Vasographic agent | |
| JP2001131056A (en) | W/o/w type multiphase emulsion | |
| WO2023060216A1 (en) | Biocompatible and allergen free lipid emulsions | |
| JPH04356417A (en) | Fat emulsion for intravenous injection | |
| JPH0547523B2 (en) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |